CClinicalTrials.gg
TerminatedNCT02834572Updated Apr 8, 2026

Using Technology to Match Young Black Men and Transwomen Who Have Sex With Men or Transwomen to HIV Testing Options

An interventional study of All About Me and Control in HIV Testing, sponsored by New York Blood Center. Terminated at 1 site in United States. Open to participants aged 16 Years to 29 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by New York Blood Center · Not applicable, Interventional, and Prevention

Why this study was terminated
PI (Koblin) at different institution
Phase
Not applicable
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
16 Years to 29 Years
Sex
All
01

Study summary

Young Black men who have sex with men (MSM) and transwomen in the US are affected by HIV at severely disproportionate rates. A key component of HIV prevention for communities at risk is diagnosing HIV infections through regular HIV testing. A significant proportion of young Black MSM and transwomen have not tested in the prior year. This research study seeks to address low HIV testing rates among young Black MSM and transwomen by testing a brief Internet-based HIV testing intervention optimized for mobile devices. The intervention takes advantage of the variety of HIV testing options now available, including the HIV self testing, couples-based HIV counseling and testing and traditional clinic-based testing and will provide men and transwomen with a tailored recommendation of their optimal HIV testing approach. The investigators are conducting a pilot randomized study among young Black MSM and transwomen followed for 6 months to estimate the intervention's potential efficacy in increasing HIV testing.

Read the detailed description

We are conducting a pilot study among 240 young Black MSM and transgender women randomized to the Intervention Arm (assessment and algorithm to deliver a tailored recommendation) or Control (assessment and standard HIV testing information) and followed for 6 months to estimate the intervention's potential efficacy in increasing HIV testing. After informed consent, participants are asked to provide contact information on the locator form. Then, participants complete a brief quantitative assessment including basic demographics, HIV testing history and other factors related to HIV testing. All participants, regardless of study arm, then receive information about each HIV testing method including how the tests are conducted (blood, oral sample), and availability of counseling and support. Participants then are randomized into 1 of the 2 study arms. A computer program will randomly assign each participant using randomly ordered block sizes of 4 and 6 and stratified by age (16-23, 24-29 years) to balance groups.

Participants assigned to the Intervention Arm will complete a brief quantitative assessment lasting approximately 2-3 minutes to assess those factors associated with HIV testing and thus are needed to complete the algorithm. They then receive the results of the HIV testing algorithm, presented as their personalized HIV testing approach. All participants will receive information on resources in New York City to test by all of these methods. The control participants are provided with the above information about each testing approach but without a recommended approach.

02

Conditions studied

  • HIV Testing
03

In context

Lead sponsor

New York Blood Center is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 29 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • male at birth;
  • self-identify as Black, African American, Caribbean Black, African Black or multiethnic Black;
  • able to read and respond in English;
  • between 16-29 years of age;
  • known to be HIV-infected;
  • insertive or receptive anal intercourse with a man or transwoman in the last 12 months;
  • reside in the New York City metropolitan area

Exclusion criteria

Exclusion Criteria:

  • enrolled in any other HIV research study involving HIV testing
  • participant in an HIV vaccine trial
  • currently taking pre-exposure prophylaxis
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
236 participants (actual)

Study arms

  • Experimental
    All About Me

    assessment and algorithm to provide participants with a tailored recommendation of their optimal HIV testing approach

    Behavioral: All About Me

  • Active comparator
    Control

    HIV testing information

    Behavioral: Control

Interventions

  • BehavioralAll About Me

    Assessment and algorithm to determine recommended HIV testing approach

  • BehavioralControl

    HIV testing information

06

What researchers measure

Primary outcomes

  1. Number of participants reporting having an HIV test as assessed by questionnaire

    Self-reported HIV test in the prior 3 months assessed by questionnaire

    Time frame: 3 months

Secondary outcomes

  1. Number of participants who are aware of HIV self-testing and couples based voluntary counseling and testing as assessed by questionnaire

    Self-reported awareness of HIV self-testing and couples based voluntary counseling and testing assessed by questionnaire

    Time frame: 3 months

  2. Number of intervention participants recommended a self-test who use a self-test as assessed by questionnaire

    Self-reported use of self test among those recommended a self test - Intervention participants only

    Time frame: 3 months

  3. Number of intervention participants recommended testing at a clinic who test at a clinic as assessed by questionnaire

    Self-reported use of testing at a clinic among those recommended to test at a clinic - Intervention participants

    Time frame: 3 months

  4. Number of intervention participants recommended couples testing who test using couples testing as assessed by questionnaire

    Self-reported use of couples testing among those recommended to test using couples testing - Intervention only

    Time frame: 3 months

07

Study locations

1 site
  • New York Blood Center
    New York, New York 10065, United States
08

References and documents

Publications

  • Frye V, Nandi V, Hirshfield S, Chiasson MA, Wilton L, Usher D, Hoover DR, Koblin BA. Brief Report: Randomized Controlled Trial of an Intervention to Match Young Black Men and Transwomen Who Have Sex With Men or Transwomen to HIV Testing Options in New York City (All About Me). J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):31-36. doi: 10.1097/QAI.0000000000002223. PubMed 31809359 ↗
  • Koblin B, Hirshfield S, Chiasson MA, Wilton L, Usher D, Nandi V, Hoover DR, Frye V. Intervention to Match Young Black Men and Transwomen Who Have Sex With Men or Transwomen to HIV Testing Options (All About Me): Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2017 Dec 19;6(12):e254. doi: 10.2196/resprot.8856. PubMed 29258976 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02834572
Lead sponsor
New York Blood Center
Responsible party
Sponsor
First posted
Jul 15, 2016
Start date
Jun 2016
Primary completion
Dec 2017
Completion
Dec 2017
Last update
Apr 8, 2026

Study contacts

Beryl Koblin, PhD
principal investigator · NY Blood Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion